Vertaling van "clinical importance " (Nederlands → Frans) :

Farmacologische handboeken, nationale en internationale formularia: Martindale 10, Geriatric Dosage Handbook 11, Managing Clinically Important Drug Interactions 12, AHFS Drug Information 13, Gecommentarieerd Geneesmiddelenrepertorium 14, Farmacotherapeutisch Kompas 15, British National Formulary 16.
Les traités de pharmacologie, les formulaires et répertoires nationaux ou internationaux: Martindale 10, Geriatric Dosage Handbook 11, Managing Clinically Important Drug Interactions 12, AHFS Drug Information 13, Répertoire Commenté des Médicaments 14, Farmacotherapeutisch Kompas 15, British National Formulary 16,.

Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with H. influenzae.
2. Une résistance de faible niveau aux fluoroquinolones (CMI pour la ciprofloxacine de 0,12 à 0,5 mg/L) peut apparaître, mais il n’y a pas de preuve que cette résistance ait une importance clinique dans les infections respiratoires dues à H. influenzae.

Gecommentarieerd Geneesmiddelenrepertorium 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .
Commenté des Médicaments 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .

The safety of participants in clinical trials with investigational products (IMP) and of the users of the authorised medicines and health products is of fundamental importance.
The safety of participants in clinical trials with investigational products (IMP) and of the users of the authorised medicines and health products is of fundamental importance.

Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).
Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).

Recently launched products provided important contributions in Oncology (USD 2.5 billion, +14% lc), which benefited from the new anti-cancer medicine Afinitor (USD 32 million) approved in 2009 and new clinical data supporting Tasigna (USD 68 million, +101% lc).
Oncologie (USD 2,5 milliards, +14% en m. l) a profité d’importantes contributions des nouveaux produits, en particulier Afinitor (USD 32 millions), médicament anticancer homologué en 2009, et de nouveaux résultats cliniques supportant Tasigna (USD 68 millions, +101% en m. l.).

The incidence of nosocomial MRSA bacteraemia is an important and robust indicator of the overall attack-rate of MRSA infection and makes it possible to assess the clinical impact of MRSA.
L’incidence de la bactériémie nosocomiale à MRSA est un indicateur important et solide du taux d'attaque global de l'infection à MRSA et permet d'évaluer l'impact clinique de MRSA.

The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference
The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference